Heartflow, Inc. Common Stock
HealthcareNASDAQ:HTFL · NASDAQ Global Select
+$2.57 today
Vol 1.89M · Avg 1.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$191.4M of revenue converted into -$111.8M of net income for the selected period. Gross margin is 77.9% and net margin is -58.2%, showing how much revenue survives after costs and taxes. EPS is $-0.88, tying the income statement back to per-share earnings.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $176.0M +39.9% | $125.8M +44.3% | $87.2M | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $40.8M +30.2% | $31.4M +7.7% | $29.1M | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $135.2M +43.1% | $94.4M +62.7% | $58.1M | $11.6B | $10.3B | $8.9B |
| Gross Margin | 76.8% +1.7pp | 75.1% +8.5pp | 66.6% | 26.4% | 45.5% | 9.8% |
| Research & Development | $64.9M +49.2% | $43.5M +21.4% | $35.9M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $134.3M +19.8% | $112.2M +17.9% | $95.1M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $199.3M +28.0% | $155.7M +18.9% | $131.0M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $8.6M +5.4% | $8.1M +7.2% | $7.6M | $419.0M | $1.2B | $374.2M |
| EBITDA | -$93.1M -42.2% | -$65.5M -4.2% | -$62.8M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | -52.9% -0.9pp | -52.0% +20.0pp | -72.1% | 14.3% | 10.0% | 5.6% |
| Operating Income | -$64.1M -4.6% | -$61.2M +16.0% | -$72.9M | $9.0B | $10.6B | $12.3B |
| Operating Margin | -36.4% +12.3pp | -48.7% +35.0pp | -83.6% | 11.2% | 18.7% | 16.6% |
| Interest Income | $5.5M +36.2% | $4.1M -25.5% | $5.5M | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $15.2M -33.4% | $22.8M -7.8% | $24.7M | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | -$52.8M -50.2% | -$35.2M -58.4% | -$22.2M | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$116.9M -21.3% | -$96.4M -1.3% | -$95.1M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | -66.4% +10.2pp | -76.6% +32.5pp | -109.1% | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | -$76.0K -243.4% | $53.0K -90.3% | $547.0K | $375.6M | $666.8M | $1.3B |
| Net Income | -$116.8M -21.1% | -$96.4M -0.8% | -$95.7M | $5.1B | $5.0B | $4.9B |
| Net Margin | -66.3% +10.3pp | -76.6% +33.1pp | -109.7% | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$0 +79.1% | -$2 +21.1% | -$2 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$0 +79.1% | -$2 +21.1% | -$2 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $368.5M +484.4% | $63.1M -1.3% | $63.9M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $368.5M +484.4% | $63.1M -1.3% | $63.9M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
LivaNova PLC
NASDAQ:LIVN
$4.36B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Surgery Partners, Inc.
NASDAQ:SGRY
$2.00B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Perrigo Company plc
NYSE:PRGO
$1.52B
Alphatec Holdings, Inc.
NASDAQ:ATEC
$1.27B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HTFL generate?
Heartflow, Inc. Common Stock (HTFL) reported $176.03M of revenue in fiscal 2025.
Is HTFL profitable?
Heartflow, Inc. Common Stock (HTFL) reported -$116,791,000.00 of net income, with a net margin of -66.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.